Big Pharma and makers of generic treatments are making money from patent settlements that delay competition and block low-priced generics, write Arthur Caplan of New York University's Langone Medical Center and his son Zachary Caplan, an attorney in Philadelphia. The U.S. Supreme Court should quickly put an end to patent settlements to encourage competition and promote better and cheaper drugs, they write.

Full Story:

Related Summaries